Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Extends Compugen Relationship, Licenses Two Protein Analysis Programs

NEW YORK, July 23-Pfizer's global R&D division has extended a deal with Compugen and licensed the Israeli bioinformatics company's biological modeling program, called Leads, as well as two protein analysis software products, Z4000 and Z3.

 

Pfizer acquired its relationship with Compugen through its purchase of Warner-Lambert in 2000. Warner-Lambert's Parke-Davis division had begun a collaboration with Compugen in 1998.

 

A Compugen press release made no mention of money.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.